Pharmaceutical and Medical Device Company
Appears in 2 stories
Developer and commercial partner for ICOTYDE
For two decades, the most effective treatments for moderate-to-severe psoriasis required needles — self-injected drugs or clinic infusions that many patients refused or abandoned. On March 18, 2026, the Food and Drug Administration (FDA) approved ICOTYDE, a once-daily pill that blocks the interleukin-23 (IL-23) receptor with the precision of an injectable biologic. In clinical trials of roughly 2,500 patients, about 70 percent achieved clear or almost clear skin at 16 weeks, with side effects within 1.1 percentage points of a placebo.
Updated Mar 18
Defendant; won reversal on implied covenant but owes damages for efforts breach
Delaware's courts have long served as the final word on American corporate disputes. On January 12, 2026, the state's Supreme Court issued a ruling that will reshape how companies structure billion-dollar acquisitions: when a merger agreement specifies a particular path to an earnout payment, courts will not rescue sellers who failed to negotiate alternatives.
Updated Feb 4
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
